CTOs on the Move

Epic Pharmacy Network

www.epicrx.com

 
Formed in 1982 and headquartered in Maryland, EPIC Pharmacies is a not-for-profit buying group of hundreds of independently owned pharmacies across the country. EPIC offers a full range of programs and services while returning its net revenues to its members throughout the year, including a year-end distribution.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.epicrx.com
  • 5024 Campbell Boulevard Suite R
    Nottingham, MD USA 21236
  • Phone: 804.379.9060

Executives

Name Title Contact Details
Luke Gordon
Vice President of Network Development Profile

Similar Companies

GPX Update

Fluidx Medical Technologys novel GPX Embolic Device is a durable embolic that is easy to use, controllable, and effective for vessel occlusion.

CareLink Community Support Services

CareLink Community Services provides a progressive approach to rehabilitation, wellness, & autonomy for people with disabilities.

DeGolers Pharmacies

DeGolers Pharmacies is a Kansas City, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AA Medical

AA Medical Store improves healthcare around the world by supplying refurbished state-of the-art surgical devices at the best price, with the best warranty, and unmatched service and support.

Dragon Pharmaceuticals

Dragon Pharmaceuticals Inc. (OTC-BB: Drug) is an international biotech company headquartered in Vancouver, Canada, with production and R&D facilities in Nanjing, China and 160 employees worldwide. The Company develops and commercializes human proteins for therapeutic use. Using superior and proprietary DNA vector technology, Dragon is able to produce high yields of quality protein drugs at low costs and high margins. Dragon is one of the world`s largest producers of Epoetin Alfa, or EPO, a therapeutic protein used to treat anemia related to kidney failure, chemotherapy, and surgery. Dragon`s EPO is approved and being marketed for use in chronic renal failure in China, Egypt, India and Peru. Additional regulatory submissions are in progress throughout Central and Eastern Europe, Southeast Asia, Latin America and the Middle East.